BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. The company is headquartered in New Haven, Connecticut and currently employs 37 full-time employees. The company went IPO on 2018-03-08. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. The company is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Follow-Up Questions
Who is the CEO of BioXcel Therapeutics Inc?
Dr. Vimal Mehta is the President of BioXcel Therapeutics Inc, joining the firm since 2017.
What is the price performance of BTAI stock?
The current price of BTAI is $1.92, it has increased 1.34% in the last trading day.
What are the primary business themes or industries for BioXcel Therapeutics Inc?
BioXcel Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is BioXcel Therapeutics Inc market cap?
BioXcel Therapeutics Inc's current market cap is $37.8M
Is BioXcel Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for BioXcel Therapeutics Inc, including 2 strong buy, 7 buy, 2 hold, 1 sell, and 2 strong sell
